Advertisement
Screener

TALPHERA, INC. (TLPH) Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic

2.8 / 5 stars · 68/120 Roast Me

TALPHERA, INC. Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic

TALPHERA, INC. (TLPH) reported Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic of -$8.11 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-06.

Discontinued › Income Statement › Other Income

us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic · last filed 2024-03-06

  • TALPHERA, INC. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2023-12-31 was -$12.00K.
  • TALPHERA, INC. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2023-09-30 was $61.00K.
  • TALPHERA, INC. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2023-06-30 was $57.00K.
  • TALPHERA, INC. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2023-03-31 was -$8.22M.
  • TALPHERA, INC. net income (loss) from discontinued operations available to common shareholders, basic for fiscal 2023 was -$8.11M.
  • TALPHERA, INC. net income (loss) from discontinued operations available to common shareholders, basic for fiscal 2022 was -$11.37M.
Period endNet Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 3 monthNet Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 6 monthNet Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 9 monthNet Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 12 month
2023-12-31-$12.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06
$49.00K
derived: sum of 2 quarters · filed 2024-03-06
$106.00K
derived: sum of 3 quarters · filed 2024-03-06
-$8.11M
10-K · filed 2024-03-06
2023-09-30$61.00K
10-Q · filed 2023-11-14
$118.00K
derived: sum of 2 quarters · filed 2023-11-14
-$8.10M
10-Q · filed 2023-11-14
-$9.65M
derived: sum of 4 quarters · filed 2024-03-06
2023-06-30$57.00K
10-Q · filed 2023-08-10
-$8.16M
10-Q · filed 2023-08-10
-$9.71M
derived: sum of 3 quarters · filed 2024-03-06
-$11.82M
derived: sum of 4 quarters · filed 2024-03-06
2023-03-31-$8.22M
derived: 10-K 12 month − 3 quarters · filed 2024-03-06
-$9.76M
derived: sum of 2 quarters · filed 2024-03-06
-$11.88M
derived: sum of 3 quarters · filed 2024-03-06
-$15.53M
derived: sum of 4 quarters · filed 2024-03-06
2022-12-31-$1.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06
-$3.66M
derived: sum of 2 quarters · filed 2024-03-06
-$7.31M
derived: sum of 3 quarters · filed 2024-03-06
-$11.37M
10-K · filed 2024-03-06
2022-09-30-$2.11M
10-Q · filed 2023-11-14
-$5.76M
derived: sum of 2 quarters · filed 2023-11-14
-$9.82M
10-Q · filed 2023-11-14
2022-06-30-$3.65M
10-Q · filed 2023-08-10
-$7.71M
10-Q · filed 2023-08-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
CalciMedica, Inc. (CALC)United States$0.061B-1.42
Skye Bioscience, Inc. (SKYE)United States$0.061B-0.48
Boundless Bio, Inc. (BOLD)United States$0.059B-0.88
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Rein Therapeutics, Inc. (RNTX)United States$0.063B-1.76
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58
HYPERION DEFI, INC. (HYPD)United States$0.065B
XBiotech Inc. (XBIT)United States$0.066B-1.56
HERON THERAPEUTICS, INC. /DE/ (HRTX)United States$0.055B-2.38
Clene Inc. (CLNN)United States$0.054B-1.99